Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Author:
Leon Bernal-Mizrachi,Ajay K. Nooka,Leonard Heffner,Craig E. Cole,Jing C. Ye,Ravi Vij,Craig C. Hofmeister,John Rushton,Zhengjia Chen,Subir Goyal,Jeffrey M. Switchenko,Sagar Lonial,Jonathan L. Kaufman
Copyright © 2021 American Society of Hematology. Published by Elsevier Inc. All rights reserved.